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AbstrAct
Barrett’s esophagus (BE) is the only well-known precursor lesion of esophageal 
adenocarcinoma (EA). The exact estimates of the annual progression rate from BE to EA 
vary from 0.07% to 3.6%. The identification of BE patients at higher risk to progress to 
EA is hence mandatory, although difficult to accomplish. In search of novel BE biomarkers 
we analyzed the efficacy of hERG1 potassium channels in predicting BE progression 
to EA. Once tested by immunohistochemistry (IHC) on bioptic samples, hERG1 was 
expressed in BE, and its expression levels increased during progression from BE to 
esophageal dysplasia (ED) and EA. hERG1 was also over-expressed in the metaplastic 
cells arising in BE lesions obtained in different BE mouse models, induced either surgically 
or chemically. Furthermore, transgenic mice which over express hERG1 in the whole 
gastrointestinal tract, developed BE lesions after an esophago-jejunal anastomosis more 
frequently, compared to controls. A case-control study was performed on 104 bioptic 
samples from newly diagnosed BE patients further followed up for at least 10 years. It 
emerged a statistically significant association between hERG1 expression status and risk 
of progression to EA. Finally, a novel fluorophore- conjugated recombinant single chain 
variable fragment antibody (scFv-hERG1-Alexa488) was tested on freshly collected live 
BE biopsies: it could recognize hERG1 positive samples, perfectly matching IHC data.
Overall, hERG1 can be considered a novel BE biomarker to be exploited for a novel 
endoscopic surveillance protocol, either in biopsies or through endoscopy, to identify 
those BE patients with higher risk to progress to EA.
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INtrODUctION 
Barrett’s esophagus (BE) is a pathologic condition 
easily detectable at endoscopy and characterized by the 
replacement of the squamous epithelium of the distal 
esophagus by a columnar-type mucosa (i.e. intestinal 
metaplasia), when biopsied [1]. The real prevalence of 
BE in the general population varies from 1.6 to 5.6%, 
depending on demographic features (sex, age, ethnicity) 
together with geographical variations [2]. Patients with 
BE have an increased risk to develop an esophageal 
adenocarcinoma (EA) [3]. Indeed BE is the only well-
known pathologic precursor of EA, a process often 
preceded by the occurrence of dysplasia (esophageal 
dysplasia, ED), with a stepwise progression from low 
grade to high grade dysplasia, and adenocarcinoma. The 
wide variation in the estimates of the annual progression 
rate of BE to EA (0.07%–3.6%) makes it mandatory 
to perform endoscopic surveillance to all BE patients. 
However, endoscopy is a highly invasive, low cost-
effective procedure. Moreover, endoscopic detection of 
dysplasia is a late diagnostic option, affected by multiple 
biases such as sampling error and subjective evaluation. 
Overall, the identification of BE patients at higher risk to 
progress to EA is difficult [4].
For these reasons, the search of BE biomarkers is 
of capital importance. Several potential biomarkers have 
been identified, and some of them have been proposed 
for proper BE diagnosis (e.g. c-MYC, HER2 [5]), others 
for prediction of progression (EGFR [6], P53 [7]) or 
for prognosis (miRNA profile [8]). Since none of the 
above biomarker has per se a clear cut valence for either 
diagnostic or prognostic purposes, the use of molecular 
panels (reviewed by [9]) has been proposed. For example, 
a panel of three molecular markers (P53, cyclin A and 
aneuploidy) has been proven to ensure a precise and 
objective diagnosis [10]. Recently, Fassan and coworkers 
[11] showed that the overall expression of transcribed 
ultra-conserved regions (T-UCR), which is altered in BE, 
ED and EA, might represent a potential novel molecular 
panel in esophageal neoplastic pathologies.
A proper screening protocol should lead to the 
identification of BE and ED lesions with the highest 
accuracy and the minimum discomfort for the patient. 
Hence biomarkers would be extremely useful if associated 
to high resolution imaging techniques (reviewed in [12]). 
To this purpose, several improvements to endoscopy, 
which represents the gold standard for BE surveillance and 
screening, have been performed. Indeed Chromoendoscopy 
and Narrow Banding Imaging (NBI), as well as the 
exploitation of autofluorescence due to endogenous 
fluorophores, greatly improved the quality of endoscopy 
images and hence the accuracy of diagnosis [13]. 
In the last twenty years the involvement of ion 
channels and transporters (ICTs) in tumor development and 
progression has gathered much attention (reviewed in [14]). 
ICTs represent novel cancer biomarkers as well as 
therapy targets. In esophageal pathologies, the potassium 
channel EAG and the non-selective cation channel TRPC 
have been identified as negative prognostic factors 
in squamous esophageal cancers (reviewed in [14]). 
Conversely, the apical sodium-dependent bile acid 
transporters (SLC10A2) is highly expressed in BE 
and EA compared to normal esophagus whereas the 
overexpression of the divalent metal transporter1 
(SLC11A2) is associated with metastatization in EA [14]. 
A peculiar role in neoplastic lesions of the upper 
gastrointestinal tract is exerted by hERG1 potassium 
channels. In particular, hERG1 is overexpressed in 
gastric cancers, where it contributes to increase VEGF-A 
secretion. hERG1 expression also identifies a subgroup of 
patients that might be treated with a combined therapy, 
using hERG1 inhibitors and anti-angiogenetic drugs 
[15]. In a small cohort of patients, hERG1 was found to 
be expressed in BE, while absent in normal esophageal 
mucosa and in gastro-esophageal reflux disease (GERD), 
with or without esophagitis [16]. 
Moving down this line, we designed the present 
study aimed at: (i) confirming hERG1 expression in 
a larger cohort of BE patients using an antibody which 
binds to a different, extracellular, epitope of the hERG1 
protein; (ii) determining the expression of hERG1 during 
BE progression to ED and EA; (iii) testing the possibility 
of considering hERG1 as a progression marker in BE to be 
further exploited for BE surveillance screenings. 
rEsULts
hErG1 is expressed in bE and its expression 
increases during esophageal tumor progression
In a previous study, performed in a relatively small 
cohort of patients, we showed that BE samples are positive 
for hERG1 expression, whereas both normal esophageal 
mucosa and GERD samples without or with esophagitis 
are hERG1 negative [16]. We first confirmed these data in 
a larger cohort of BE samples (125 patients instead of 27), 
applying a different antibody. Instead of the anti hERG1 
polyclonal antibody, we used an anti-hERG1 monoclonal 
antibody (Mab-hERG1, Dival Toscana Srl; Sesto 
Fiorentino, Italy) which recognizes an extra-cellular 
epitope (the S5-P loop) of the hERG1 protein and can 
be used without permeabilization. Overall, the Mab-
hERG1 gives a clearer immunohistochemical signal, with 
easiness of interpretation [17]. As shown in Figure 1, 
a clear positivity for hERG1 can be observed in the 
metaplastic cells characterizing BE lesions (Figure 1C), 
while no hERG1 expression could be detected either in 
normal squamous epithelium (Figure 1A) or in areas 
displaying signs of esophagitis (Figure 1B). Overall, 
hERG1 was expressed in 48% (60/125) of BE samples 
(see also the black bar addressed as “BE” in Figure 1I). 
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A representative example of a hERG1 positive BE sample 
is reported in Figure 1C, while a hERG1 negative sample 
is in Figure 1D. Two main isoforms of the hERG1 protein 
(the full length hERG1A and the N-terminus deleted 
hERG1B) exists and are simultaneously expressed in 
some types of cancer [18]. Since the Mab-hERG1 does 
not discriminate between hERG1A and hERG1B, we 
performed an IHC assay using the anti-hERG1B antibody 
to determine whether such isoform is expressed in BE 
lesions. As evident in Figure 1E, no hERG1B expression 
can be detected in BE metaplastic cells, whereas a 
strong hERG1B signal is evident in muscle cells of the 
surrounding stroma, as expected [19, 20]. 
Overall, these results confirm that hERG1, and 
in particular the hERG1A isoform, is expressed in 
metaplastic cells characterizing BE lesions [16], and 
show the robustness (lower background and easiness of 
interpretation) of using the Mab-hERG1. 
We also defined a scoring system, taking into 
account both the percentage of labeled cells and the 
staining intensity (from 0 to 3). The complete score was 
obtained by multiplying the two values and was therefore 
ranging from 0 (negative) to 300. Considering only 
positive samples (i.e. with scores >1), it emerged that 
BE samples have a median score equal to 145.0 ± 86.0 
(n = 60). Sixteen ED and twenty-five EA cases were also 
collected and analyzed. Five cases, for which the entire 
progression from BE to ED and then to EA was available, 
were fully analyzed and scored. Pictures relative to one of 
such cases are shown in Figure 1F–1H. Overall, hERG1 
was expressed in 87.5% (14/16) ED and 96% (24/25) EA 
(Figure 1I). Applying the scoring system described above, 
BE samples showed a significantly lower median score 
(145.0 ± 86.0), compared to ED (255.0 ± 70.7, BE vs ED 
p = 0.023) and EA (270.0 ± 48.4, BE vs EA p < 0.0001) 
(Figure 1J). We analyzed the BE, ED and EA scorings of 
Figure 1: hErG1 expression in human esophageal carcinogenesis. IHC was performed as described in Materials and Methods 
with anti-hERG1 monoclonal antibody. (A) Normal esophagus. (b) Esophagitis. (c) Representative BE sample expressing the hERG1 
protein. (D) Representative BE sample negative for hERG1 expression. (E) Representative example of IHC performed with anti-hERG1B 
antibody (Dival Toscana Srl, Sesto Fiorentino) in a BE sample. (F–H) BE (panel F), Esophageal Dysplasia (ED, panel G) and Esophageal 
Adenocarcinoma (EA, panel H) of a representative patient whose lesion progressed towards malignancy. Original magnification 20×. Scale 
bar: 100 µm. (I) Histogram summarizing hERG1 expression in the three different groups of samples analyzed (BE, ED and EA). White 
bars: hERG1 negative samples, Black bars: hERG1-positive samples. (J) Histogram summarizing hERG1 scoring in the different groups 
(BE, ED and EA). Samples were scored as described in Materials and Methods. Analysis performed using 2-sided Student’s T test revealed 
statistically significant differences between BE and ED (p = 0.023) and between BE and EA (p < 0.0001). (K) Histogram summarizing 
hERG1 scoring in the different samples (BE, ED and EA) of 5 representative patients. White bars: BE; Grey bars: ED; Black bars: EA.
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those five cases for which the entire pathology progression 
was available: hERG1 positive BE samples showed a 
trend to increase hERG1 expression during progression 
(Figure 1K and Supplementary Table S1). 
Collectively, these data show that hERG1 is 
expressed in roughly half of BE samples, and its 
expression quantitatively increases during BE progression 
to adenocarcinoma. 
hErG1 is expressed in bE lesions of bE mouse 
models
We also developed, and tested for hERG1 
expression, different BE mouse models, in which BE 
lesions were induced either surgically or chemically. 
For the “surgical” model, mice (either CD1 or Balb-C) 
were subjected to an esophago-jejunal anastomosis (EJA) 
(Figure 2A.1–2A.3). Mice were sacrificed 9 to 12 months 
after surgery and the esophagus, the stomach and intestine 
were removed, and analyzed for the detection of BE 
lesions through hematoxylin and eosin as well as Alcian 
blue staining (Figure 2A.4). All the operated animals 
showed signs of gastric mucosal atrophy due to the EJA 
(Figure 2A.2 and 2A.3). 4 out of 11 (36%) operated 
animals developed histologically detectable intestinal 
metaplasia in the lower esophagus, indicative of BE 
(Figure 2A.5, red arrow). One mouse also showed signs 
of ED in an area surrounding a BE lesion (yellow arrow 
in Figure 2A.5). 
The “chemical” model was based on chronic 
esophageal inflammation: IL-1β transgenic (TG) mice 
received, in their drinking water, 0.2% deoxycholic acid 
(DCA) for 7 months of treatment (see the scheme in 
Figure 2B.1). Four out of 10 (40%) IL-1β TG DCA-treated 
mice developed histologically detectable BE lesions 
(Figure 2B.2).
An IHC analysis was performed in order to 
evaluate the expression of hERG1 in BE lesions of both 
mouse models. hERG1 was absent in either normal 
(see black arrow in Figure 2A.5, Figure 2A.6 upper 
panel, Figure 2B.3 and Figure 2B.4 upper panel) or 
inflamed (esophagitis) esophageal tissue in both models 
(Supplementary Figure S2), while it is up-regulated in 
BE lesions arising in both types of models (Figure 2A.5, 
Figure 2B.3, Figure 2B.4 lower panel and Figure 2C.1 left 
panel) (mean score = 130.0 ± 28.7 in the surgical model 
and mean score = 113.0 ± 37 in the chemical model) as 
well as in the dysplasia observed in the surgical model 
(mean score = 270.0) (Figure 2C.1 right panel). 
Finally, we tested the EJA surgical procedure in 
mice overexpressing hERG1. To this purpose, we operated 
FVB hERG1 transgenic (TG) mice whose hERG1 over-
expression in the GI tract was proven in [21]. To detect 
intestinal metaplasia, the Alcian Blue staining was applied 
(Figure 2C.2), as above. All (4/4) the FVB hERG1 TG 
mice developed BE lesions 9–12 months after surgery 
(Figure 2C.3).
hErG1 is an indicator of bE progression to 
adenocarcinoma
We then tested whether hERG1 might represent a 
biomarker of tumor progression in BE. A case-control 
study design was chosen to analyze the potential 
association between a rare medical condition (EA in BE) 
and a relatively common marker (hERG1 expression). We 
analyzed 104 samples with a bioptic diagnosis of BE at the 
onset and a follow-up of at least 10 years, provided from 
different institutions in Italy. Both samples that progressed 
towards ED and/or EA in the follow-up time (pBE, n = 26) 
and samples belonging to patients whose lesions did 
not progress to EA (npBE, n = 78) were collected. For 
this analysis samples were simply scored as “negative” 
or “positive” for hERG1 expression. Representative 
examples of a npBE sample, which does not express the 
hERG1 protein, and of a pBE sample, which is positive 
for hERG1 expression are shown in Figure 3A and 3B, 
respectively. Overall, hERG1 is expressed in 19 out of 
26 pBE (73.1%) while only 42.3% (33 out of 78) npBE 
expressed hERG1 (Figure 3C). The analysis of the 
case-control study indicated a statistically significant 
association between BE hERG1 expression status and risk 
of progression to adenocarcinoma (odds ratio = 3.70, 95% 
CI: 1.40–9.82; P = 0.006) (Table 1). It is worth noting 
that hERG1 positivity in pBE is not comparable with that 
observed in the whole series, since, in the case-control 
study, we only focused on selected patients whose lesions 
progressed towards ED or EA. The distribution analysis of 
the samples according to a more complex scoring system 
did not highlight any trend (see Supplementary Figure S1). 
We also analyzed hERG1 expression in either ED 
or EA lesions (which available) of the 26 pBE patients. 
Those 20 BE samples that were hERG1 positive 
maintained their positivity and increased the scoring in 
table 1: statistical analysis for the case-control retrospective study
npbE (%) pbE (%) Or 95% cI P value(Likelihood ratio test)
hERG1 − 45 (57.7%) 7 (26.9%)
3.70 1.40–9.82 P = 0.006*
hErG1 + 33 (42.3%) 19 (73.1%)
Abbreviations: npBE: not progressed BE, pBE: progressed BE.
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Figure 2: hErG1 is up-regulated in bE mouse models: (A.1) surgical procedure: drawing of the EJA performed in 
this study. (A.2) Representative specimen from an operated animal, showing EJA. (A.3) EJA at the moment of the sacrifice: the yellow 
arrow indicates the esophagus, the white one indicates the atrophic stomach. (A.4) Alcian Blue staining performed on Balb-C mice in order 
to detect goblet cells. (A.5) IHC performed on Balb-C mice, in order to evaluate hERG1 expression, indicates that hERG1 is not expressed 
in normal esophageal tissue (black arrow) while it is up-regulated in metaplasia (red arrow) and dysplasia (yellow arrow). (A.6) Higher 
magnification microphotographs showing IHC performed in normal squamous tissue (upper panel) and BE (lower panel). (b.1) Birth and 
screening of IL-1β TG mice F1 generations: each founder mouse is bred with a Wild Type partner. The IL-β TG mice are treated with 0,2% 
DCA for 7 months and then sacrificed. Alcian Blue (b.2) and IHC (b.3) staining performed on IL-1β TG mice DCA-treated in order to 
detect BE lesions and to evaluate hERG1 expression. (b.4) Higher magnification microphotographs showing IHC performed in normal 
squamous tissue (upper panel) and BE (lower panel). (c.1) A detail of metaplastic area (left) and dysplastic area (right) of a Balb-C mouse 
sample. hERG1 is up-regulated in BE lesions (with low score) and in dysplasia (with high score) as detailed in Results. (c.3) Alcian Blue 
staining shows BE lesion in hERG1 TG mice Scale bar 100 µm. Original magnifications, 20× (A.4, A.5, B.2, B.3, C.1, c.2) ) and 40× (A.6, 
B. 4). C.3) Histogram showing the percentage of mice that developed BE. Grey bar: wild type operated mice (wt); black bar: hERG1 TG 
mice operated as described in Materials and Methods. IHC performed on hERG1 TG mice confirm the HERG1-positive labelling. 
Oncotarget59540www.impactjournals.com/oncotarget
the ED/EA lesions (mean values 161.8 ± 31.3 and 237.3 
± 16.9, respectively). The ED/EA lesions of four hERG1 
negative BE cases became positive (Table 2). This made 
the percentage of positive cases to increase from 76.9% to 
92.3%. The significance of this result was confirmed by 
the McNemar’s Test (p = 0.045, Supplementary Table S2). 
scFv-hErG1-alexa488 test on fresh surgical 
esophageal biopsies
The data described above indicated that hERG1 
expression could help in identifying patients at higher risk 
of progressing from BE to adenocarcinoma. We therefore 
tested the immunoreactivity of a scFv-hERG1, derived 
from the anti-hERG1 monoclonal antibody (Duranti, Sette, 
manuscript in preparation), labeled with the Alexa488 
fluorophore. With the aim of further testing the scFv-
hERG1-Alexa488 in endoscopy to discriminate between 
hERG1-positive and hERG1-negative BE patients,   we 
tested such antibody fragment on fresh endoscopic 
mucosal samples from BE patients. IHC with the Mab-
hERG1 was carried out on parallel paraffin-embedded 
samples. Figure 4 shows representative images of either 
fresh samples (panel A) or fixed samples (panel B). 
Samples with an intense IHC signal, also displayed a 
positive IF signal. The mean IHC and IF values, calculated 
as described in the figure legend, were used to perform 
a statistical analysis, applying the Spearman Correlation 
Test. A statistically significant value was obtained 
(P = 0.00031), with a coefficient of 0.986. Figure 4C 
shows a scatter plot with the concordance between IHC 
and IF staining.
DIscUssION
EA has a very poor prognosis mainly due to lack 
of early diagnosis and complex therapeutic approaches. 
BE is the only well-known precursor of EA, and for 
table 2: hErG1 expression in patient-matched pbE, ED/EA included in the case-control study
pbE ED EA
bs1 + N/A +
bs2 + N/A +
bs3 + + +
bs4 + N/A +
bs5 + + N/A
bs6 − + N/A
bs7 + N/A +
bs8 + + +
bs9 − N/A +
bs10 + + +
FI1 + N/A +
FI2 + N/A +
FI3 + N/A +
FI4 + N/A +
FI5 + N/A +
FI6 + N/A +
sI1 + + N/A
sI2 + + N/A
sI3 − − N/A
sI4 − − −
sI5 + + +
sI6 + + N/A
sI7 − + N/A
sI8 + + N/A
sI9 + + N/A
sI10 + + N/A
Abbreviations: N/A: histological sample not available for IHC evaluation.
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this reason endoscopic surveillance protocols have been 
proposed for BE patients. However, due to the wide 
variation in the estimates of the progression rate from BE 
to EA (0.07%–3.6%), and the lack of validated biomarkers 
of BE progression, a higher number of BE patients than 
necessary are subjected to invasive endoscopic and bioptic 
procedures. This justifies the fact that currently there are 
no evidences that BE screening effectively reduces EA 
incidence and mortality [22]. 
In search of novel BE biomarkers, we here provide 
evidence that hERG1 channels can be considered novel 
markers of progression in BE patients. In particular, we 
applied a specific anti-hERG1 monoclonal antibody, 
which recognizes an extracellular epitope of the protein 
and can hence be used in IHC without permeabilization. 
Through this procedure, we showed that (a) the hERG1 
protein is overexpressed in BE, confirming a previous 
pilot study [16], and that the prevalent hERG1 isoform 
is hERG1A, as occurs in the majority of solid cancers 
examined so far [15, 23, 24]. On the other hand, we found 
a strong expression of the hERG1B isoform in smooth 
muscle cells of the submucosa, as described in rodents 
[19, 20, 25]. After applying an IHC scoring system, 
based on the contemporary assessment of the percentage 
of labelled cells and the signal intensity, we also 
proved that (b) hERG1 expression increases along BE 
progression to ED and EA. This was proven in separate 
cohorts of BE, ED and EA samples (Figure 1I and 1J) 
as well as in a subset of patients whose BE lesions 
progressed to ED or EA and for which matched BE and 
ED/EA samples were available (Figure 1K,Table 2 and 
Supplementary Table S1). 
We then tested whether hERG1 expression 
could be detected in different BE mouse models, to be 
exploited in the future for preclinical in vivo imaging 
and pharmacological studies. In particular, we confirmed 
hERG1 expression in the metaplastic cells arising in 
BE lesions of two different mouse models: a surgically-
induced and a chemically-induced model. Moreover, in 
one mouse in which BE progressed to ED, the scoring 
of hERG1 expression increased. Interestingly, we also 
found that the percentage of mice developing BE after the 
surgical procedure greatly increased (from 36% to 100%) 
in transgenic mice which over express the hERG1 gene in 
the GI tract, including the esophagus [21]. Although these 
results were obtained in a small subset of animals, they 
might suggest a potential causative role of hERG1 in BE 
pathogenesis, a topic to be further studied in the future.
Figure 3: hErG1 expression along tumor progression. (A) Non-progressed BE. The representative sample here reported is 
negative for hERG1 expression. (b) Progressed BE. A representative hERG1-positive sample is shown. Original magnification 20×. 
Scale bar: 100 mm. (c) Histogram showing hERG1 expression in progressed (pBE) and non-progressed BE (npBE). White bars: hERG1 
negative; Black bars: hERG1 positive.
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The main translational result of the present 
paper was that obtained through a case-control study, 
in which the association between hERG1 expression 
and development of adenocarcinoma was evaluated in 
samples from patients’ biopsies collected at the diagnosis 
of BE. Patients enrolled in the study had a follow up 
of at least 10 years, so that the progression to EA had 
been adequately monitored. Our data demonstrated a 
statistically significant association between hERG1 
expression status in BE patients and risk of progression 
to EA (odds ratio = 3.70, 95% CI: 1.40–9.82; P = 0.006) 
(Table 1). In other words, hERG1 represents a progression 
factor that contributes to identify high-risk BE patients. 
Nevertheless, since the percentage of hERG1-positive 
pBE samples is not strikingly different from hERG1-
positive npBE (although the statistically significant results 
reached), extreme caution should be applied, to take into 
account false-positive samples. 
Over the years it has become clear that hERG1 plays 
a relevant role in several types of cancer. In particular, 
hERG1 is a marker of advanced stage in colorectal 
cancers [23], where it contributes to identify high 
risk TNM stage II patients [17, Muratori L , Petroni G 
et al., submitted]. In gastric [15] and pancreatic cancers 
[26] hERG1 is a prognostic biomarker also in early 
stages cancers, contributing to identifying patients 
with worse prognosis. Such different scenarios should 
be related to the modulatory effects that hERG1 exerts 
on intracellular signaling pathways which control cell 
proliferation, survival, invasiveness, VEGF-A secretion 
and in turn angiogenesis (reviewed in [25]). The mis-
expression of hERG1 in esophageal mucosa, even at 
early stages of esophageal cancerogenesis, could in turn 
modify cellular behavior switching on survival and pro-
angiogenic signals, which in turn promote proliferation of 
BE metaplastic cells [27]. 
Figure 4: scFv-hErG1-Alexa488 test on fresh surgical esophageal biopsies. Representative images of Immunofluorescence 
with scFv-hERG1-Alexa488 (A) and corresponding immunohistochemical analysis with anti-hERG1 monoclonal antibody (b). Scale bar: 
100mm. Original Magnification: 10× (A), 20× (B). (c) Scatter plot, with standard error, showing the concordance between IHC and IF. 
Each point represents a BE patient. IHC staining: hERG1 expression was evaluated applying, for three areas of BE lesion from each sample, 
an immunohistochemical score obtained through the combination of the estimate of the percentage of immunoreactive cells (quantity score) 
with the estimate of staining intensity (staining intensity score). The raw data were converted to the combined score by multiplying the 
percentage and staining intensity values, obtaining a value between 0 and 300 for each area and finally the mean of the three areas was 
computed for each sample (mean score: 57, 103, 0, 127, 0, 123); IF staining: for each sample the measures of three different areas of the 
image with the strongest fluorescent scFv-hERG1-Alexa488 was performed with Image J. The mean of the three measures, obtained from 
negative control, was calculated and this value was subtracted in each result of the three different areas of other samples and then for all 
samples the average was computed (obtained values: 21.696, 27.361, 7.320, 48.346, 4.041, 40.367).
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In the field of esophageal diseases, hERG1 
could be used to better identify BE patients at high 
risk to progress alone or in combination with other 
progression indicators. Nowadays, the detection 
of dysplasia is the commonest histopathological 
progression marker. Besides being a late marker of 
progression, it is also affected by several biases such 
as biopsy sampling error, subjective evaluation and 
possibility of regression, at least in low grade ED. For 
these reasons, other progression markers have been 
proposed such as 9p and 17p loss of heterozigosity 
(LOH) and aneuploidy [5–10, 28]. Recently, P53 
immunohistochemical evaluation has been proposed as 
a progression marker, although the wide variation in the 
expression as well as the high false-positive and false-
negative rates limit its usefulness (reviewed in [29]). 
The immunohistochemical evaluation of hERG1 on 
biopsies obtained during endoscopic procedures would 
help to better diagnose BE patients at high risk of 
progressing towards EA. The possibility of including 
other BE progression predictive biomarkers in the IHC 
procedure could be of great advantage, reducing false 
positive results. Overall, once clinically validated, a 
panel of biomarkers including hERG1 could help to 
design the most useful surveillance or treatment protocol. 
Finally, to address the problems dealing with 
the clinical management of BE surveillance, we 
provided data which allow us to propose a different 
and simpler approach. We tested an Alexa-conjugated 
scFv-hERG1 antibody which recognizes an epitope 
located extracellularly and can hence be used without 
permeabilization, on freshly collected, live endoscopic 
BE biopsies. The good concordance between IF 
(with the scFv-hERG1-Alexa488) and IHC (with the 
Mab-hERG1) allows us to propose the scFv-hERG1-
Alexa488 as a novel tool for optical in vivo imaging. 
For in vivo imaging procedures, scFvs are preferred 
with respect to whole antibody molecules, due to their 
small size (25–30 kDa), that allows them to penetrate 
solid tumor mass. Indeed, Sturm et al. [30] recently 
showed that a fluorescently-labelled peptide can be 
safely administered to patients and revealed by confocal 
endomicroscopy to successfully identify ED and EA. 
Moreover, scFvs are ideal vectors for the delivery of 
agents such as radionuclides, enzymes, drugs or toxins 
in vivo [31–34]. After proper testing for safety, the scFv-
hERG1-Alexa488 might be used in the future within 
standard endoscopic procedures and novel targeted-
imaging techniques (reviewed in [13]). 
Overall, data reported in the present paper indicate 
that hERG1 identifies patients at higher risk to progress 
towards EA, and open the possibility of developing a new 
protocol for the surveillance of BE patients by the in vivo 
direct detection of hERG1-positive and hERG1-negative 
BE patients, using the scFv-hERG1-Alexa488.
MAtErIALs AND MEtHODs
Patients and tissue specimens
Tissue samples were obtained from different 
institutions belonging to GIRCG (Department of Clinical 
and Experimental Medicine, University of Florence; 
Pathology Division, Azienda Ospedaliero-Universitaria 
Senese; Pathology Division, Borgo Trento Hospital, Verona; 
Pathology Division, Morgagni-Pierantoni Hospital, Forlì; 
Pathology Division, Esine Hospital, ASL Vallecamonica 
Sebino; Insitute of Pathology, Spedali Civili, Brescia). 
A total of 125 BE, 16 ED and 25 EA paraffin-embedded 
samples were collected. 
Diagnosis and histological grading were assessed 
in all cases using standard criteria by experienced 
pathologists (LM, CV, AT, LS, MC, MS and VV).
Immunohistochemistry
 Immunohistochemistry was performed as 
previously reported [17] using an anti-hERG1 monoclonal 
antibody directed against the S5-pore region (Dival 
Toscana Srl, Sesto Fiorentino, Italy) at 1:200 dilution. 
Immunohistochemistry for hERG1B was performed 
following the same protocol with the exception of 
permeabilization, carried out by adding Triton X-100 to the 
blocking solution. The antibody (purified polyclonal anti-
hERG1B antibody, Dival Toscana Srl, Sesto Fiorentino, 
Italy) was used at a final dilution 1:1000. Slides were 
incubated overnight at 4°C and immunostaining was 
performed with a commercially available kit (PicTure Max 
kit and DAB, Invitrogen; Carlsbad CA, USA). 
scoring assessment
 Samples were evaluated applying a scoring system 
frequently used for cytoplasmic and membrane proteins 
[26]. Such scoring system combines the estimate of the 
percentage of positive cells with the staining intensity. 
Staining intensity was rated on a scale of 0–3, with 
0 = negative; 1 = weak; 2 = moderate, and 3 = strong. 
The raw data were converted to the combined score by 
multiplying the percentage and staining intensity values, 
obtaining a value between 0 and 300 for each sample. Only 
samples with a complete score equal to 0 were considered 
negative. All the samples were evaluated using Leica DMR 
light microscope (Leica; Wetzlar, Germany). Samples 
were evaluated and scored by three independent operators 
(EL, TL and JI). 
case-control study
Cases were defined as BE subjects whose lesions 
progressed towards dysplasia/adenocarcinoma while 
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Controls were BE patients, with at least a followup visit 
completed during the last 10 years, whose lesions didn’t 
progress at the last time when they were examined. 
Since there may be a considerable lag time between the 
diagnosis of BE and the progression towards EA, the date 
of BE diagnosis was defined as index date. Three controls 
were individually matched per case for age at the index 
date and gender. Controls were randomly chosen, without 
replacement, between all individuals with a followup 
duration equal to or longer than the interval between index 
date and EA diagnosis in the corresponding case.
We calculated that, for a twosided alpha error equal 
to 5%, with 15 cases available, a casecontrol ratio equal 
to 1:3, and a prevalence of hERG1 expression between 
controls equal to 10%, the study will have a power of 
80% against a minimal detectable relative risk (odds 
ratio) of 6.7. According to our previous data, such a strong 
association should be plausible.
scFv-hErG1-Alexa488 test on fresh surgical 
esophageal biopsies 
Endoscopic mucosal samples from six BE patients 
were collected from the Department of Surgery and 
Translational Medicine, University of Florence, under a 
protocol approved by the Local Ethic Committee. Two 
consecutive samples of fresh biopsies of about 2–3 mm 
in diameter were harvested during endoscopic procedures 
from the site of BE lesion of each patient, checking each 
site of biopsy with enhanced endoscopy (NBI – Olympus). 
Immediately a sample was immersed in PBS 1X and 
used for experiments with scFv-hERG1-Alexa488 (see 
below); the other sample was put in 3.7% formaldehyde 
for fixation, paraffin embedding and immunohistochemical 
staining with anti-hERG1 monoclonal antibody. 
Immunohistochemistry was performed as previously 
described [17] without permeabilization and hERG1 
expression was evaluated applying, for three areas of 
BE lesion from each sample, an immunohistochemical 
score obtained through the combination of the estimate of 
the percentage of immunoreactive cells (quantity score) 
with the estimate of staining intensity (staining intensity 
score). Staining intensity was rated on a scale of 0–3, with 
0 = negative; 1 = weak; 2 = moderate, and 3 = strong. 
The raw data were converted to the combined score by 
multiplying the percentage and staining intensity values, 
obtaining a value between 0 and 300 for each area and finally 
the mean of the three areas was computed for each sample. 
Experiments with scFv-hERG1-Alexa488 were 
performed using a recombinant scFv-hERG1 (patent N° 
FI2014A000189) directed against the S5-pore region 
and derived from the anti-hERG1 monoclonal antibody 
(Duranti, Sette et al, manuscript in preparation). Briefly, 
the variable immunoglobulin domains of heavy and light 
chain of hERG1-mAb were cloned into the expression 
vector pPIC9K to produce a His-tag protein in Pichia 
Pastoris. For further applications, scFv-hERG1 antibody 
large-scale production was necessary: for these purposes, 
large-scale cultures were set up following and validating 
a protocol useful both for batch and bioreactor protein 
production. The scFV was labeled with Alexa Fluor 488 
Microscale Protein Labeling kit (Thermofisher Scientific; 
CA, USA). For staining live bioptic samples the following 
protocol was applied: fresh, non-fixed tissue samples, 
orientated with the mucosal layer facing upwards, 
were laid on an agarose liquid surface homogeneously 
distributed on Cell Culture Chamber Slide (Euroclone; 
Milan, Italy). Biopsies were incubated in the dark with 
scFv-hERG1-Alexa488, diluted 1:20 in PBS 1×, at 4°C 
overnight. The following day samples were washed three 
times with PBS 1X before and after performing Hoechst 
staining (1:1000 in PBS 1×) for 30 min. The negative 
control was considered one of the sample before the 
incubation with scFv-hERG1-Alexa488. 
In this study a directed light fluorescence 
microscope Leica DMR, (Leica; Wetzlar, Germany) was 
used. During the scanning, after the focus of the sample 
performed through Hoechst stain, the laser delivers the 
488 nm excitation wavelength to measure the scFv-
hERG1-Alexa488 signal. The images were captured at the 
same time of exposure for all biopsies for later download 
and processing. The images were analyzed using Image J 
software. The image with the strongest fluorescent scFv-
hERG1-Alexa488 signal was chosen for each sample 
and the measure of three different areas was performed. 
The mean of the three measures, obtained from negative 
control, was calculated and this value was subtracted in 
each result of the three different areas of other samples and 
then for all samples the average was computed. 
Induction of bE in mice
In vivo experiments were performed at the 
Laboratory of Genetic Engineering for the Production 
of Animal Models (LIGeMA) at the Animal House of 
the University of Florence (Ce.S.A.L.). All experiments 
have been carried out in accordance with the Principles of 
Laboratory Animal Care (directive 86/609/EEC). 
Balb-C, CD-1 mice (2–4 months of age, weighing 
24–29g) and FVB hERG1 transgenic mice (2–4 months of 
age, weighing 23–30g), overexpressing hERG1 in GI tract 
[18], were operated to perform gastro-jejunal anastomosis 
(EJA), inducing gastro duodenal mixed reflux. Anesthesia 
was performed by an intraperitoneal injection of Avertin 
2.5% (16 μg/g body weight). 
Surgery was performed by placing the mouse on a 
small surgical table and, after a 2–3 cm median incision 
of the skin and peritoneum, the esophagogastric junction 
was exposed. Distal esophagus was sectioned after 
clamping in order to prevent esophageal retraction and 
the gastric side ligated with dexon 6/0 suture and the 
continuity of the gastrointestinal tract restored by end-
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to-side esophago-jejunal anastomosis with 7/0 silk suture 
(Figure 2 A.1– 2 A.3). After repositioning of the viscera 
the abdominal wall was closed with nylon 4/0. Mice were 
sacrificed after 9 and 12 months. Furthermore, another 
set of experiment was performed using a chemical model 
of BE treating four 3-month-old 10 IL-1β TG mice [35] 
with 0.2% deoxycholic acid (DCA) in the drinking water 
(pH 7.0). Human IL-1β transgenic mice were generated 
by targeting expression of hIL-1β to the esophagus using 
the Epstein Barr virus promoter, as proven in [35], and 
screened using human IL-1β specific PCR primers. 7–8 
months after the beginning of the DCA-treatment mice 
were sacrificed.
After the animal sacrifice the stomach and esophagus 
were removed and fixed in 4% formalin for 24 hours. 
Thereafter, samples were processed for paraffin embedding 
and 7 µm longitudinal cut sections were obtained through 
a microtome and put on positive-charged slides.
Samples were stained with Hematoxylin/Eosin and 
Alcian Blue standardized protocols to detect goblet cells 
and then observed under a light microscope. Moreover, 
samples were stained with anti-hERG1 polyclonal antibody, 
in order to evaluate the expression of hERG1 channel. The 
antibody was diluted in UltraVBlock (Bio-Optica; Milan, 
Italy) in PBS1:10 (v/v) at a final dilution 1:200 [23].
statistical analysis 
For the case-control study, the estimates of the odds 
ratio and its 95% confidence interval were obtained from 
a logistic regression model. Statistical analyses were 
performed by LB using SAS version 9.2 (SAS Institute, 
Cary, NC).
The comparison between hERG1 expression in 
paired pBE and ED/EA was evaluated by McNemar’s test 
(P < 0.05).
The association between the value of scFv-hERG1-
Alexa488 signal and immunohistochemical score of 
anti-hERG1 monoclonal antibody was analyzed using 
the Spearman correlation test. P < 0.05 was considered 
statistically significant. 
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